Cantor Fitzgerald Comments on Ardelyx FY2026 Earnings

Ardelyx, Inc. (NASDAQ:ARDX - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2026 earnings estimates for Ardelyx in a research report issued to clients and investors on Monday, June 9th. Cantor Fitzgerald analyst P. Agrawal expects that the biopharmaceutical company will post earnings per share of ($0.05) for the year. Cantor Fitzgerald currently has a "Strong-Buy" rating on the stock. The consensus estimate for Ardelyx's current full-year earnings is ($0.18) per share.

Other equities research analysts also recently issued research reports about the stock. LADENBURG THALM/SH SH reaffirmed a "buy" rating and set a $11.00 price objective on shares of Ardelyx in a research report on Friday, March 7th. Scotiabank initiated coverage on Ardelyx in a research report on Friday, March 7th. They set a "sector outperform" rating and a $15.00 price objective for the company. Piper Sandler raised Ardelyx to a "hold" rating in a research report on Wednesday, March 12th. Raymond James cut Ardelyx from a "strong-buy" rating to an "outperform" rating and set a $11.00 target price on the stock. in a research note on Friday, May 2nd. Finally, Wall Street Zen downgraded shares of Ardelyx from a "hold" rating to a "sell" rating in a report on Monday, May 5th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $10.39.

Ardelyx Stock Performance

Shares of NASDAQ:ARDX traded down $0.12 on Tuesday, reaching $3.60. 5,999,529 shares of the company's stock were exchanged, compared to its average volume of 4,534,869. The business's 50-day moving average is $4.18 and its two-hundred day moving average is $4.90. The company has a quick ratio of 4.31, a current ratio of 4.58 and a debt-to-equity ratio of 0.87. Ardelyx has a fifty-two week low of $3.21 and a fifty-two week high of $8.06. The firm has a market capitalization of $861.32 million, a price-to-earnings ratio of -22.50 and a beta of 0.59.

Ardelyx (NASDAQ:ARDX - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.07). The firm had revenue of $74.11 million for the quarter, compared to analyst estimates of $79.40 million. Ardelyx had a negative net margin of 11.73% and a negative return on equity of 24.87%. The business's revenue was up 61.1% on a year-over-year basis. During the same period in the prior year, the company posted ($0.11) earnings per share.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ARDX. Vanguard Group Inc. lifted its holdings in Ardelyx by 5.6% in the 4th quarter. Vanguard Group Inc. now owns 14,362,659 shares of the biopharmaceutical company's stock valued at $72,819,000 after acquiring an additional 767,111 shares during the last quarter. Barclays PLC raised its holdings in shares of Ardelyx by 24.9% in the 3rd quarter. Barclays PLC now owns 547,325 shares of the biopharmaceutical company's stock worth $3,770,000 after purchasing an additional 109,285 shares in the last quarter. Two Sigma Advisers LP lifted its stake in Ardelyx by 206.7% during the fourth quarter. Two Sigma Advisers LP now owns 593,700 shares of the biopharmaceutical company's stock valued at $3,010,000 after purchasing an additional 400,100 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Ardelyx by 5.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,035,135 shares of the biopharmaceutical company's stock valued at $10,318,000 after purchasing an additional 96,357 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Ardelyx by 32.6% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 578,256 shares of the biopharmaceutical company's stock worth $2,932,000 after buying an additional 142,294 shares in the last quarter. 58.92% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director David M. Mott acquired 200,000 shares of the company's stock in a transaction dated Monday, June 9th. The shares were bought at an average price of $3.69 per share, with a total value of $738,000.00. Following the purchase, the director now owns 2,696,871 shares of the company's stock, valued at approximately $9,951,453.99. This represents a 8.01% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Michael Raab sold 41,666 shares of the company's stock in a transaction on Friday, April 4th. The shares were sold at an average price of $4.59, for a total value of $191,246.94. Following the completion of the sale, the chief executive officer now owns 1,615,587 shares of the company's stock, valued at approximately $7,415,544.33. This trade represents a 2.51% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders acquired 681,377 shares of company stock worth $2,676,411 and sold 166,809 shares worth $708,914. 4.80% of the stock is currently owned by insiders.

Ardelyx Company Profile

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.